本项目通过流行病学调查、动物实验、体外细胞分子生物学实验开展肌醇六磷酸(IP6)及其次级磷酸化形式对结直肠癌(CRC)的发生及肠道菌群影响研究。体外模拟肠道环境，分离提纯IP6次级磷酸化水解产物及制备富含IP3的水解混合物，通过细胞分子生物学实验研究IP6及IP6次级磷酸化形式的不同抗癌作用，同时深入探讨它们通过PI3K/Akt信号通路发挥抗CRC作用的机制；通过建立诱癌和移植瘤动物模型，观察IP6对肠道菌群构成变化、细菌产植酸酶活力的影响，并研究IP6及其次级磷酸化形式的抗CRC作用；通过病例-对照研究，探讨膳食IP6的摄入与CRC患病风险性，同时采用肠道菌群分离鉴定和肠道菌群16s宏基因组测序分析方法，分析肿瘤患者肠道菌群构成，探讨人体肠道菌群及细菌产植酸酶活力与CRC患病风险性的关系。该项目的研究将会为IP6的抗CRC作用提供更全面的证据。

The research will focus on the effects of inositol hexaphosphate (IP6) and its hydrolysates on the risk of colorectal cancer (CRC) and the compositon change of intestinal microbiota by epidemiological investigation, animal models and cellular experiments in vitro. The anticancer activity of IP6, the purified IP6 hydrolysates and IP3-rich IP6 hydrolysate(IP3-RIH) on mamalian cells in vitro under simulated intestinal enviroment will be elucidated and the mechanism of their anti-CRC role through the PI3K/Akt signal pathway will be explored as well.The effect of IP6 intake on gut microbota distribution and microbial phytase activity variance will be further investigated in animal models of carcinogenesis and the anti-CRC role of IP6 and its hydrolysates will be evaluated in the same model.Furthermore,we will determine the relationship between IP6 intake and the risk of CRC in China through case-control study, expolre the composition change of human gut microbota and the contribution of change in gut microbota and the microbial phytase activity variance to the risk of CRC by 16s rRNA metagenomic sequncing and tranditional culture techniques.The well done project will provide comprehesive evidence of the novel role of IP6 anti-CRC.